The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, hematological conditions, and cancer. With ongoing clinical trials ...
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback